
The most recognized mechanism by which peroxisome proliferators regulated gene expresssion is through a PPAR/RXR heterodimeric complex binding to a peroxisome proliferator-response element (PPRE) (classical mechanism). However, there are the possibility of several variations on this theme: 1). The peroxisome proliferator interacts with PPAR that preexists as a DNA complex with associated corepressors proteins. The interaction with ligand causes release of the corepressor and association with a coactivator, resulting in the classical mechanism. 2). The peroxisome proliferator interacts with PPAR as a soluble member of the nucleus. The binding of ligand results in RXR heterodimerization, DNA binding and coactivator recruitment. 3). In this scenario, PPAR exists in the cytosol, perhaps complexed to heat shock protein 90 and/or other chaperones. Binding of peroxisome proliferator causes a conformational change and translocation into the nucleus. Scenarios 4 and 5 require regulation of gene expression via non-classical mechanisms: 4). PPAR is capable of interacting with, and forming DNA binding heterodimers with, several nuclear receptors including the thyroid hormone receptor. The binding site for this non-RXR heterodimer need not be the classic DR-1 motif found in the PPRE. 5). PPAR may participate in the regulation of gene expression witout binding to DNA. By association with transcription factors such as c-jun or p65, PPAR diminishes the ability of AP1 or NFB to bind to their cognate DNA sequences, respectively. Also shown in this scheme are two means to modify the peroxisome proliferator response. Most importantly, growth factor signaling has a pronounced affect on PPAR via post-translational modification. PPAR is a phosphoprotein and its activity is affected by insulin. Several kinase pathways affects PPARa's activity, although the specific kinases and phosphorylation sites have not been conclusively determined.
Contributor: Jack Vanden Heuvel
REFERENCES: Escher, P. and Wahli, W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res, 448: 121-138, 2000 Gelman, L., Fruchart, J.C., and Auwerx, J. And update on the mechanisms of action of the perxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci, 55: 932-943, 1999 Kersten, S., Desvergne, B., and Wahli, W. Roles of PPARs in health and disease. Nature, 405: 421-424, 2000 Peters, J.M, and Vanden Heuvel, J.P. Peroxisomes, peroxisome proliferators and peroxisiome proliferator-activated receptors (PPARs). In: J.P. vanden Heuvel, G.H. Perdew, W.B. Mattes and W.F. Greenlee (eds.), Cellular and Molecular Toxicology, Vol. 14, pp. Peters, J.M, and Vanden Heuvel, J.P. Peroxisomes, peroxisom Vanden Heuvel, J.P. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci, 47: 1-8, 1993
蛋白质作为构成人体组织器官的支架和主要物质,在人体生命活动中起着重要作用。蛋白质的相互作用能产生许多效应,如形成特异底物作用通道、生成新的结合位点、失活、作用底物专一性和动力学变化等,细胞的代谢、信号......
2021年9月9日,无锡臻和生物科技有限公司(以下简称“臻和科技”)与美国VyantBio公司签署TissueofOrigin®(以下简称“TOO®”)全球权益和ZL转让协议,全资收购这款唯一获FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同时撤回了中国学者49篇文章。从2019年开始,Journalo......
磷酸甘油酸突变酶1(PGAM1)通过其代谢活性以及与其他蛋白质(例如α平滑肌肌动蛋白(ACTA2))的相互作用,在癌症代谢和肿瘤进展中起关键作用。变构调节被认为是发现针对PGAM1的高选择性和有效抑制......
2018年12月6日,来自圣迭戈的消息——Illumina公司(纳斯达克股票代码:ILMN)今天宣布推出新型高密度基因分型芯片Infinium™GlobalDiversityArray。这款芯片设计源......
来自杜克大学生物学系,基因组科学与政策研究院(InstituteforGenomeSciencesandPolicy)的研究人员发现人类和黑猩猩之间的差异并不如我们之前认为的那么大——其中99%都是相......
SDS-PAGE异常电泳现象及分析SDS-PAGEHallofShame.pdf 很不错的东东~~推荐下~......
今天在网上淘到的一本书GeneFlowfromGMPlants,05年,还算比较新。望大家多多支持。GeneFlowfromGMPlantsEditedbyGUYM.POPPYSchoolofBiol......
摘要基于高通量数据,研究人员已经设计了许多算法用于寻找功能完全未知蛋白质的功能.然而,这些算法的效率受到一些根本因素的制约,包括:(ⅰ)功能完全未知的蛋白质参与一个精细功能的先验概率低;(ⅱ)高通量互......
摘要GESTs(geneexpressionsimilarityandtaxonomysimilarity)是结合基因表达相似性和基因功能分类体系GeneOntology(GO)中的功能概念相似性测度......